deltatrials
Completed PHASE2 NCT00510926

Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

CML/021 A Phase II Exploratory Study of IMATINIB High Dose (800mg/gg) in the Treatment of Newly Diagnosed Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

Sponsor: University of Bologna

Conditions Myeloid Leukemia, Chronic, Chronic-Phase
Interventions Imatinib Mesilate (Glivec)
Updated 4 times since 2017 Last updated: Aug 2, 2007 Started: Jan 31, 2004 Completion: Nov 30, 2006

Listed as NCT00510926, this PHASE2 trial focuses on Myeloid Leukemia, Chronic, Chronic-Phase and remains completed. Sponsored by University of Bologna, it has been updated 4 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2017 — Jan 2021 [monthly]

    Completed PHASE2

    First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Bologna
Data source: University of Bologna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bologna, Italy